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Aim To systematically assess the existing literature on ethi-
cal aspects of human biobanks.
Method We searched the Web of Science and PubMed 
databases to find studies addressing ethical problems in 
biobanks with no limits set (study design, study popula-
tion, time period, or language of publication). All identified 
articles published until November 2010 were included. We 
analyzed the type of published articles, journals publishing 
them, involvement of countries/institutions, year of pub-
lication, and citations received, and qualitatively assessed 
every article in order to identify ethical issues addressed by 
the majority of published research on human biobanking.
Results Hundred and fifty four studies satisfied our re-
view criteria. The studies mainly came from highly devel-
oped countries and were all published in the last two de-
cades, with over half of them published in 2009 or 2010. 
They  most  commonly  discussed  the  informed  consent, 
privacy and identifiability, return of results to participants, 
importance of public trust, involvement of children, com-
mercialization, the role of ethics boards, international data 
exchange, ownership of samples, and benefit sharing.
Conclusions The focus on ethical aspects is strongly pres-
ent through the whole biobanking research field. Although 
there is a consensus on the old and most typical ethical is-
sues, with further development of the field and increasing-
ly complex structure of human biobanks, these issues will 
likely continue to arise and accumulate, hence requiring 
constant re-appraisal and continuing discussion.
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Biobanks comprise organized collections of human biolog-
ical samples, usually associated personal health informa-
tion, which are used together for biomedical research. Re-
search results are generally very important for the society 
and biobanks have been heavily supported by many gov-
ernments. Thus, in the recent few years biobanks have un-
dergone rapid proliferation and have become increasingly 
complex. Their complexity has arisen from an increasingly 
diverse set of research purposes, and of types and sources 
of the samples. For instance, biobanks could comprise the 
collections of human bodily substances of all kinds, such 
as cells, tissues, blood, or DNA. They range in capacity from 
small collections of samples to large-scale national reposi-
tories. The collected samples could be population-based 
or disease-specific, originating from diverse profile of indi-
viduals, eg, minors or adult persons. Biobanks may contain 
anonymous human samples or samples linked to the spe-
cific personal information. Also, there are various purposes 
of biobanks, such as diagnostic, therapeutic, or research. 
Biobanks could be an ownership of public or private sub-
jects, the latter being non-profit or profit based. As a con-
sequence, such a diversity of biobanking is associated with 
a broad spectrum of ethical and legal issues (1-5).
Ethical issues are commonly present in many aspects of 
biobanking. The fact that biobanks deal with human sam-
ples,  invading  an  individual  autonomy  or  limiting  self-
control, provokes a number of ethical issues. Who is ac-
tually competent to give informed consent and donate a 
sample? When individuals donate part of their body to a 
biobank, how is that human sample processed? Who is the 
owner of the sample? Who should decide how it should 
be used? Who has the right to know individual results of 
research? These and many more ethical dilemmas exist in 
the ethical framework of biobanks. With the recent rapid 
developments in biobanking, all of these issues are mag-
nified with plenty of further new questions continuously 
arising. Ethical framework has been the most controversial 
issue in the domain of biobanking. Thus, it is not surpris-
ing that there is a substantial literature focusing on ethical 
dilemas in biobanking, such as informed consent, privacy, 
protection, and returning of results to participants (6-9).
Due to these reasons, it is very important that research-
ers are provided with a current review of the literature 
on the ethics of biobanking in a systematic way, to doc-
ument the latest consensus on ethical issues in biobank-
ing and to highlight emerging issues. For that purpose, we 
reviewed the existing literature on ethical aspects of hu-
man biobanks. We aimed to develop a systematic frame-
work for categorizing ethical concerns relevant to human 
biobanks and to monitor the impact of research into eth-
ical issues. This could help the ethical boards in decision 
making when dealing with issues within the framework of 
biobanking. Moreover, we believe that such kind of work 
could stimulate policymakers and lawmakers to create an 
adequate legal framework for biobanking, an important, 
but still largely unregulated issue.
MeTHODs
search strategy
This study was based on a systematic literature search, aim-
ing to identify all relevant studies that fit into the domain 
of ethical issues in biobanking. We initially searched Web 
of Science (WOS) database using all combinations of the 
search terms “ethics OR ethical” AND “biobank*”. In addi-
tion, we cross-checked our findings with the PubMed da-
tabase and searched for additional sources of information. 
No other limits were set (study design, study population, 
time period, or language of publication) in order to provide 
a comprehensive set of results. The search period was from 
January 1950 to November 2010, and the search was per-
formed in December 2010.
selection criteria
We used a four-phase flow diagram from the Preferred Re-
porting Items for Systematic Reviews and Meta-Analyses 
Guidelines to improve the quality of inclusion criteria (10). 
Initially, we included all retrieved articles from both data-
bases, and first eliminated all double entries. All retrieved 
publications were then manually reviewed. We excluded 
those  that  were  mentioning  both  terms  (biobanks  and 
ethics), but not necessarily related to each other in the text. 
Also, we excluded the articles that only marginally men-
tioned ethics, but it was not the focus of the article.
Analysis of findings
All included studies were analyzed in two ways. First, we 
analyzed the type of published work, journals publishing 
the articles, author’s affiliations (countries and institutions), 
year of publication, and citations received. Additionally, we 
qualitatively assessed every article in order to identify ethi-
cal issues addressed by the majority of published research 
on human biobanking. This was done based on catego-
rization of all included publications according to spe-
cific independent ethical issues, until saturation of REVIEW ARTICLE 264 Croat Med J. 2011; 52: 262-79
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each category was achieved. We reviewed the articles in 
each category and summarized the main messages, which 
are described in subheadings in this review. This was done 
independently by DB and IR, and their results were com-
pared and discussed, until an agreement was reached.
ResulTs
The results of the search were very similar in both WOS and 
PubMed databases. The initial search returned 198 articles 
cited in WOS and 231 articles cited in PubMed in the 1950-
2010 period. In spite of no time period limit, all articles were 
published after 1998, which was expected concerning the 
time of biobank establishment. There were only a handful 
of articles in WOS that were not in PubMed, and about 40 
articles in PubMed that were not in WOS.
We excluded 22 articles from WOS due to lack of relevance 
(they mentioned the terms biobanks and ethics, but not 
related to each other). After a careful reading, additional 
28 articles were excluded that did not have ethics as the 
actual focus. In addition, we examined additional 40 ar-
ticles found on PubMed and excluded 34 articles. Finally, 
we retained 154 articles (148 articles from WOS and 6 from 
PubMed) that addressed ethical issues related to the devel-
opment and use of human biobanks.
scientometric analysis of the included papers
Among the 154 retained articles, most were original research 
articles (64.2%), followed by review articles (18.2%), editorial 
material (5.2%), and other less frequently present types (Ta-
ble 1). They were most commonly found in Pathobiology, Eu-
ropean Journal of Human Genetics, and Public Health Genom-
ics, each containing about 5% of the included articles (Table 
2). Only 34 articles included investigation of people’s opin-
ion (ie, empirical data), while the rest dealt with theoretical 
ethical problems and debate of ethical issues.
Most of the studies were published in a few highly devel-
oped countries (USA, UK, Canada, Sweden, and Denmark). 
In more than 80% of the articles, at least one author came 
from these countries (Table 3). Other articles came mostly 
from southwestern and northwestern Europe, particular-
ly France, Spain, Italy, Germany, Norway, the Netherlands, 
and Belgium. Apart from a few articles from Australia, ar-
ticles from other parts of world, such as Eastern Europe, 
Asia, Africa, or South America, were very rare. The institu-
tions most involved in this discussion were the University 
of Copenhagen (Denmark), Uppsala University (Sweden), 
Karolinska Institute (Sweden), and University of British Co-
lumbia (Canada), followed by several US-based universi-
ties (Table 3). Only 20% of all articles received (or at least 
acknowledged receipt of) some kind of funding support, 
mostly from the European Commission (3.3%), National 
Human Genome Research Institute (3.3%), and European 
Union (2.6%) (Table 4).
Although the first biobanks were established nearly two de-
cades ago, more than a half of the retained titles were pub-
lished in the last two years (Figure 1), illustrating a marked 
increase in interest. A near-perfect agreement was noticed 
between the number of articles and the number of cita-
tions (Figure 2), which increased greatly in 2009 and 2010. 
These indicate that ethical aspects of human biobanks are 
a very fast-evolving field.
We also tried to identify the articles that represented the 
most intensely cited contributions within this area of re-
search to date. We used WOS to investigate the number 
of citations received for each study. The analysis of citation 
was focused on intensity (citations per year), rather than 
on a total number of received citations, because the latter 
TABle 1. Type of published document related to key words 
“ethics,” “ethical,” and “biobank” during 1999-2010 period
Rank Document type Number (%)
1 Original research articles 99 (64.2)
2 Review 28 (18.2)
3 Editorial material   8 (5.2)
4 Proceedings article   7 (4.5)
5 News item   3 (1.9)
6 Book   3 (1.9)
7 Letter   3 (1.9)
8 Meeting abstract   3 (1.9)
TABle 2. Ten journals most frequently involved in publishing 
articles related to ethics in developing biobanks during 1999-
2010 period
Rank Journal
Number (% 
of articles
 1 Pathobiology 9 (5.8)
 2 European Journal of Human Genetics 8 (5.2)
 3 Public Health Genomics 8 (5.2)
 4 American Journal of Medical Genetics Part A 5 (3.3)
 5 Journal of Law, Medicine & Ethics 5 (3.3)
 6 Journal of Medical Ethics 5 (3.3)
 7 Personalized medicine 5 (3.3)
 8 Annual Review of Genomics and 
Human Genetics
4 (2.6)
 9 Medicine, Health Care and Philosophy 4 (2.6)
10 New Genetics and Society 4 (2.6)265 Budimir et al: Ethical aspects of biobanks
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is largely influenced by the amount of time that elapsed 
since publication, while the former is a more stable indi-
cator that becomes very informative within the first year 
from  publication.  Among  154  articles,  only  16  received 
more than 5 citations per year (ie, about 10%). The topics 
found in cited articles were most commonly presentation 
of a few current ethical dilemmas, informed consent, prob-
lems in genetic biobanks, and integration of biobanks.
The most intensely cited article was the study of Hansson 
et al (2006) with 10.40 citations per year (11) (Table 5). This 
article discussed advantages for accepting a broad consent 
framework for future research. As we previously found that 
most articles discussed informed consent and especially its 
type, it was not surprising that this article was most inten-
sively cited by other authors. The article by Secko et al that 
also ranked quite high on our list, also discussed informed 
consent (12). It reported on a public debate over informed 
consent and offered worthwhile contributions and poten-
tial help in the governance of biobanks.
The article by Haga et al (2008) discussed general ethical 
dilemmas in human genetic biobanks (13). The article was 
TABle 4. Ten most involved institutions that provided support 
for publishing articles related to ethics in developing biobanks 
during 1999-2010 period
Rank Funding Agency
Number (%)  
of articles
 1 European Commission 5 (3.3)
 2 National Human Genome Research Institute 5 (3.3)
 3 European Union 4 (2.6)
 4 FWO Flanders 3 (1.9)
 5 Genome BC 3 (1.9)
 6 National Institutes of Health 3 (1.9)
 7 Canadian Tumor Repository Network CTRNet 2 (1.3)
 8 Chair Ethics Office 2 (1.3)
 9 Fondos de Investigacion Sanitaria 2 (1.3)
10 Fundación Caja Navarra 2 (1.3)
TABle 3. Contribution of 10 most involved countries and in-
stitutions that published titles related to ethics in developing 
biobanks during 1999-2010 period
Rank Publication source
Number (%) 
of articles
Country
 1 USA 53 (34.4)
 2 England 25 (16.2)
 3 Canada 20 (12.9)
 4 Sweden 20 (12.9)
 5 France 19 (12.3)
 6 Spain 17 (11.0)
 7 Germany 15 (9.7)
 8 Denmark 14 (9.1)
 9 Italy 14 (9.1)
10 Netherlands 12 (7.8)
Institution
 1 University of Copenhagen 12 (7.8)
 2 Uppsala University   9 (5.8)
 3 Karolinska Institutet   8 (5.2)
 4 University of British Columbia   8 (5.2)
 5 Facultés De Médecine De Toulouse   7 (4.5)
 6 Université de Montréal   7 (4.5)
 7 Baylor College of Medicine   6 (3.9)
 8 Indiana University   6 (3.9)
 9 Katholieke Universiteit Leuven   6 (3.9)
10 Stanford University   6 (3.9)
Figure 1.
The yearly distribution of published articles related to ethics in biobanks 
during 1999-2010 period.
Figure 2.
The yearly distribution of citations of publications related to ethics in 
biobanks during 1999-2010 period.REVIEW ARTICLE 266 Croat Med J. 2011; 52: 262-79
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attractive as it presented the most common ethical issues 
illustrated  by  experiences  of  several  national  biobanks. 
Other  articles  that  discussed  general  ethical  problems 
were also highly cited (7,9), which was expected because 
they covered numerous current ethical problems.
The article by Heglesson et al (8) discussed the ethics of 
the use of previously collected samples. Other important 
and cited articles discussed heterogeneous ethical issues 
related mostly to genomic biobanking (13-19). Genomic 
biobanks obviously need to deal with the most controver-
sial ethical issues and provoke extensive discussion. These 
studies discussed many common ethical issues, all mag-
nified in genomic biobanks, in an empirical or theoretical 
way and presented current trends or proposed solutions.
It is also interesting that among the most frequently cited ar-
ticles, several were related to proposed mechanisms of inte-
gration and harmonization of biobanks (20,21). This implies 
that both are broadly recognized as desirable, but very diffi-
cult to achieve. There is no doubt that harmonization would 
provide more efficient progress in research, but many ethi-
cal and legal problems are yet to be resolved. We believe 
that this discussion will continue and perhaps increase in fu-
ture until the most appropriate agreements are achieved.
It is also clear that the research on human induced pluripo-
tent stem cells is increasingly contributing to this debate. 
The article by Aalto-Setälä et al from 2009 (22) discussed 
the consent process for the donation of somatic cells to 
derive  pluripotent  cells. The  article  received  a  relatively 
TABle 5. The most citied articles in the field of ethics and biobanks, which received 5 or more citations per year
Rank First author Title Journal Year
Cumulative 
citation
Citations 
per year
 1 Hansson MG Should donors be allowed to give broad consent 
to future biobank research?
Lancet Oncology 2006 52 10.40
 2 Yuille M Biobanking for Europe Briefings in Bioinformatics 2008 25   8.33
 3 Caulfield T Research ethics recommendations for whole-
genome research: Consensus statement
PloS Biology 2008 23   7.67
 4 Hoeyer K Informed consent and biobanks: a population-
based study of attitudes toward tissue donation 
for genetic research
Scandinavian Journal of 
Public Health
2004 51   7.29
 5 Cambon-Thomsen A Science and society - The social and ethical issues 
of post-genomic human biobanks
Nature Reviews Genetics 2004 50   7.14
 6 Greely HT The uneasy ethical and legal underpinnings of 
large-scale genomic biobanks
Annual Review of Genomics 
and Human Genetics
2007 28   7.00
 7 Cambon-Thomsen A Trends in ethical and legal frameworks for the 
use of human biobanks
European Respiratory Journal 2007 27   6.75
 8 Gulcher JR Protection of privacy by third-party encryption 
in genetic research in Iceland
European Journal Of Human 
Genetics
2000 72   6.55
 9 Haga SB Ethical, legal, and social implications of 
biobanks for genetics research
Genetic Dissection of 
Complex Traits, 2nd Edition
2008 13   6.50
10 Helgesson G Ethical framework for previously collected biobank 
samples
Nature Biotechnology 2007 26   6.50
11 Secko DM Informed consent in biobank research: 
A deliberative approach to the debate
Social Science & Medicine 2009 13   6.50
12 Hansson MG Ethics and biobanks British Journal of Cancer 2009 12   6.00
13 Kettis-Lindblad A Genetic research and donation of tissue samples 
to biobanks. What do potential sample donors in 
the Swedish general public think?
European Journal of Public 
Health
2006 29   5.80
14 van Veen EB TuBaFrost 3: Regulatory and ethical issues on the 
exchange of residual tissue for research across 
Europe
European Journal of Cancer 2006 23   5.75
15 Lee SSJ Research 2.0: social networking and direct-to-
consumer (DTC) genomics
American Journal of Bioethics 2009 11   5.50
16 Aalto-Setala K Obtaining consent for future research with in-
duced pluripotent cells: opportunities and 
challenges
PloS Biology 2009 10   5.00267 Budimir et al: Ethical aspects of biobanks
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large number of citations in a short time period by intro-
ducing an emerging ethical problem.
Content analysis of the included articles
The first aim of the qualitative analysis was to identify sepa-
rate ethical issues that were addressed by the body of pub-
lished research. The ethical issue most often discussed was 
the consent to participate in research. It was mentioned 
as the only topic in as many as one quarter of all included 
articles, and as one of several ethical topics in additional 
25%. The role of incompetent participants, especially chil-
dren, was discussed in 15 articles, mostly as the only topic. 
In general, a larger number of other ethical issues were dis-
cussed together. Privacy and identifiability was mentioned 
in 18 articles, return of results to research participants in 
11, and importance of public trust in 10 articles. Only a 
few studies discussed commercialization, the role of eth-
ics boards, international data exchange, the ownership of 
samples, and benefit sharing.
We present each of these categories of ethical issues sepa-
rately. We begin with informed consent since this was the 
most commonly discussed issue, followed by other ethical 
issues that emerged to the present date.
Informed consent
The topic most frequently discussed was consent for par-
ticipation in research. Consent allows individuals to protect 
their right to decide whether and how their body parts 
will be used in research. Accordingly, all authors strongly 
agreed that participants should not participate and not 
be exposed to any risk of research without their consent. 
They also agreed that before obtaining consent, all partici-
pants must be well-informed and understand the purpose 
of research with its expected benefits and risks. Only af-
ter that, a voluntary consent can be obtained from each 
participant. Most of the authors also supported the op-
portunity of each participant to withdraw their consent 
(6,23-26), because this ensures additional protection and 
respect for the participants. However, withdrawal of con-
sent opens further issues: what exactly can be withdrawn, 
and at which point of study? There is no consensus over 
this problem at this time (9,25).
Discordance in opinion was also found in relation to the 
type of consent. Some authors advocated a universal, stan-
dardized consent form (27,28), as this would be practi-
cal and ensure comparability. Others disagreed and sug-
gested that geographical, social, and religious differences 
must be respected, together with different research pur-
poses, and that these cannot be addressed in a satisfactory 
way through an universal and standardized consent form 
(29,30). Some authors even proposed their own forms of 
universal  standardized  consent  (27,28,31,32)  to  facilitate 
future  biobank-based  research  from  the  ethics  point  of 
view. However, there is still no consensus in the literature 
about which approach should be adopted.
Nevertheless, most articles focused on the most appropri-
ate content of the informed consent form. Is an informed 
consent, which contains all details about research, the 
most ethical one? Or can broad or even blanket consents, 
which do not contain detailed information, be consid-
ered to be satisfactory in some situations? How can the 
latter be accepted if the purpose of consent is to eluci-
date all details about research and if they do not provide 
any specific information? In spite of these concerns, the 
majority of authors supported the contention that broad 
consent is the most applicable for the future research, in 
which the details of research are not known at the time 
when the consent is obtained. These situations are often 
present in genetic research. However, authors proposed 
some  conditions  that  must  be  respected  when  using 
broad consent: research must be of great importance, a 
maximum protection of privacy must be guaranteed to 
participants, they must be allowed anytime to withdraw 
the  consent,  and  every  future  research  should  be  ap-
proved by an ethical review board (ERB) (6,7,11,17,26,33-
43). Furthermore, if patients have indicated that they do 
not wish to participate in any future research, this deci-
sion must be respected.
It has been acknowledged that re-contacting the study 
participants to provide additional or new consent for ev-
ery future research question or technology can be very im-
practical, time consuming, expensive, and even confusing 
(or harassing or worrying) to the participants. Thus, broad 
consent has an advantage that it does not require re-con-
tact. Only in the case when participants give a broad con-
sent, a re-consent is not required. In all other cases, a re-
consent must be sought from participants (17,44).
An important problem that is not often discussed is what 
should be done in the case of participant’s death? Asking 
for re-consent is impossible, but should research be con-
tinued as it cannot harm the participant anymore? The 
few authors that addressed this topic offered the view 
that human samples can be used in every such case, REVIEW ARTICLE 268 Croat Med J. 2011; 52: 262-79
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except when there was a previously expressed wish not to 
use the samples for any future research (6,26,35).
Another concern that was raised was whether it was ac-
ceptable to use the samples that did not have consent in 
cases when it was not realistically possible to obtain it. For 
example, there are very large collections of human sam-
ples collected for diagnostic or clinical purposes that can 
be useful in research. In most cases, it is impossible to re-
contact people to obtain an informed consent, although it 
would be the most ethical way of respecting their autono-
my. But, if re-contact is not possible and these samples are 
not utilized, the potential for research could be significant-
ly reduced. Therefore, most of the authors agree that the 
use of such samples in research could be permitted with-
out consent if they are fully anonymized or carry a minimal 
risk of breaking privacy and thus should not harm the do-
nors; however, every such research must be approved by 
an ERB (6,8,26,33,34,45-57).
Privacy and identifiability of the samples
Protection of the identity of research participants is one of 
the most fundamental ethical issues. The major harm risk 
in biobanks is associated with breaking privacy (6). The first 
step in the process of protection, which biobanks broad-
ly  accept,  is  the  requirement  of  informed  consent  (58). 
Biobanks, mostly genetic ones, usually store genomic in-
formation that is linked to a particular phenotype. That link 
between two types of information presents a major threat 
to  individual’s  privacy  (16,59,60). There  is  a  widespread 
concern that insurance companies and employers could 
access personal information. They usually have great inter-
est in personal information and biobanks must guarantee 
adequate protection of personal data. Further, results of re-
search can also harm not only individuals, but the whole 
groups  could  feel  stigmatized  because  of  their  genetic 
predisposition or other relevant information. Biobanks that 
perform research on a specific ethnic or other group of 
people must consider this and be very careful when pub-
lishing the results.
These examples warn us that ethical concerns of protection 
and privacy must be respected in all aspects of biobank 
framework (61-63). Biobanks have thus proposed several 
levels of protection for personal data, but none seems to 
guarantee a complete protection (17). Using anonymous 
or anonymized samples (no link to other data or a de-
stroyed link) is the best way to protect personal infor-
mation. But this seriously limits the research utility 
(16,24,34,64), especially the potential to transform biobanks 
into longitudinal epidemiological studies. In the case of 
destruction of the samples, many biobanks could not ad-
equately utilize these data, and genetic biobanks could not 
utilize them at all. For example, the link between genomic 
and phenotypic information can be broken. Also, re-con-
tacting specific participants to provide new informed con-
sent is unachievable. There is no possibility of returning 
the results. Withdrawal of consent also becomes impos-
sible to carry out in practice. So, many authors refuse per-
manent anonymization and support coding of information 
as the most appropriate way of ensuring privacy. There is 
an agreement that simple coding, double-coding, or even 
triple-coding (one to three codes are needed to provide a 
link between sample and data) are acceptable in standard 
research practice, and at the same time are safe enough to 
ensure a satisfactory level of privacy (7,17,64-68).
This fundamental concern about privacy is usually also the 
main concern of the participants when they are deciding 
whether to donate their samples to biobanks. One study 
showed that up to 90% of people were concerned about 
their privacy (69). Thus, consequences of breaking privacy 
could substantially affect public’s willingness to participate 
and substantially delay the research. Therefore, biobanks 
must always guarantee a maximal level of protection of 
participants (6,70).
Returning the results to the examinees
A general ethical standard requires that each individual has 
“the right to know and the right not to know” the results of 
research. A result can be of statistical, clinical, and research 
interest, but also can be incidental. So, which results of re-
search should be returned to participants of the study? 
When should they be returned, and under what circum-
stances? How should they be returned and communicated 
and by whom (with what level of training)?
The  issue  of  return  of  results  has  sparked  a  broad  de-
bate about ethical implications of biobanking. Although 
very few articles confirm that participants actually have 
a substantial level of interest in getting their personal re-
search  results  back  (71,72),  it  appears  that  most  of  the 
authors do not advocate returning the individual results 
(6,7,9,17,26,34,59,73,74). They warn that returning the in-
formation can be misinterpreted and cause anxiety among 
the participants, especially if information is not of any clini-
cal relevance. Misinterpretation is referred to clinically ir-
relevant result, or results that are not yet validated, un-269 Budimir et al: Ethical aspects of biobanks
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derstood properly, or informative. These results can cause 
psychological, social, or economic harm to participants. 
But, if a result is clinically important, is it ethical not to re-
turn it? Furthermore, how are clinically important results 
best defined?
Most of the authors agree that the only exception to the 
general rule of not returning the results can be a result of 
very high clinical importance. Such a result should be re-
turned and communicated properly and professionally to 
each participant. This could be in the form of either a re-
search finding or an incidental finding. There needs to be 
an effective mechanism of prevention available, or a proper 
treatment, which could substantially improve or even save 
someone’s life. However, the main purpose of biobank-
related research is not genetic counseling of donors, but 
rather increased knowledge leading to a longer term col-
lective  improvement  of  health.  Researchers  involved  in 
biobanks have an obligation to publish all relevant scien-
tific information that could help the society as a whole.
In practice, the governing policy of most biobanks is not 
to return any individual results to their participants. How-
ever, a number of authors agree that this is not always eth-
ical (17,75). Biobanks should consider returning the find-
ings of high clinical relevance to participants. However, it 
is also acknowledged that the policy of not returning the 
results often provides a kind of protection against incorrect 
results (perhaps due to less stringent quality control mea-
sures than are found in an accredited clinical laboratory) 
and against results causing harm to the participant.
ensuring and sustaining public trust
The most important prerequisite for successful biobank-
related research is ensuring the public trust. This can be 
achieved  through  continuous  education  of  people  and 
protection of privacy. Depletion of public trust can have 
damaging consequences in biobanking, but the main vic-
tims are the people who expect improvements from medi-
cine and health systems (6).
All the reviewed articles that investigated public opinion 
on biobanks confirmed that people were generally en-
thusiastic and supportive of biobanks and were genuinely 
willing to participate (15,19,69,76-82). Some of them did 
not really understand the actual purpose of biobanking, 
but they wanted to participate nevertheless (83-86). Sev-
eral articles also confirmed that people who were more 
educated and informed about biobanking were also more 
willing to participate (12,87). Many deliberative events in 
Canada are thus being held regularly to ensure public trust 
and facilitate their engagement (12,88-90). During such 
events, people are encouraged to learn, debate, and dis-
cuss the aims and goals of biobanks. All articles confirmed 
that these events were useful in stimulating the citizens 
and  providing  greater  public  engagement  in  research, 
but also helped in structuring the governance of biobanks 
(12,88-90).
It seems that at the present time biobanks have admira-
ble levels of support from the public. However, they must 
continue to maintain and improve levels of public trust. 
Providing consent and protection of privacy are obligato-
ry elements of that process (91,92). As a few articles con-
firmed, ERB are especially important as subjects of public 
trust (6,15,19,93) and they often play an exceptionally im-
portant role in the biobank success.
Children and incompetent adults as study participants
Involving children in biobanks raises ethical dilemmas that 
are not entirely analogous to adults’ involvement. Children 
(or more precisely – minors) have a limited capacity to 
understand the ethical and other issues surrounding the 
biobanks and thus represent the most vulnerable popu-
lation. The majority of biobanks do not involve children 
because  of  special  ethical  problems  and  concerns  that 
are not easily addressable, and also because the increased 
sensitivity of the public and the media toward this seg-
ment of the population sometimes makes it an unneces-
sary risk that many biobanks are not willing to take. How-
ever, this could lead medical research on children to lag 
behind the research on adults. From the ethical point of 
view, in that way children will eventually suffer relatively 
more than adults. So, nearly all authors support the idea 
of involving children in biobanks, but they also agree that 
the risk for them should be actively minimized (94-101). 
Because children require extra protection, some authors 
even suggested that data sharing on children should be 
banned until children reach adulthood and give specific 
consent to share their samples from population databanks 
(102). However, other authors strongly opposed this sug-
gestion, arguing that such proposal would seriously delay 
research on children – possibly leaving the whole genera-
tion behind (103-105).
Furthermore, although parents will be expected to be 
very interested in having the results of research find-
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of the authors agree that this would not be an ethically ac-
ceptable policy (96,106). Parents do have a right to decide 
whether they want to involve their children in a biobank 
and they also have a right to give informed consent in-
stead of the children. However, the children must decide 
if they want to know about their own results when they 
reach adulthood. Another cause for concern is that, if par-
ents knew some genetic information of clinical relevance 
later in life, they could demand treatments for children as 
if they already had the condition, in order to protect them. 
But, what should be done with incidental findings that 
could potentially save a child’s life? Not many authors dis-
cussed this issue, but one article (106) suggested that it 
would be ethical to return this information to parents.
Besides obtaining parental informed consent, it is a gener-
al opinion that researchers must also ask for consent from 
children whenever it is possible (95). In some instances, re-
search can be conducted without parental or child’s con-
sent. These situations are rare, but must ensure minimal or 
no risk for children. Researchers must always respect the 
child’s fear and/or disagreement to participate. An ethical 
board must be consulted in every research study carried 
out on children in order to protect the interests of the child 
(95,97,107).
Although it is only rarely mentioned in the literature, similar 
ethical principles also apply to incompetent participants – 
for example, those suffering from psychiatric diseases. They 
must always be closely protected and exposed to an abso-
lutely minimal risk. A guardian must sign informed consent 
and an ethical board must be consulted in all cases to pro-
tect the interests of incompetent adults (26,108).
Commercialization
Although biobanks have a primary focus on research and 
improving medical knowledge, this will not necessarily pre-
vent private companies from trying to use biobank data for 
their own interest. In general, commercialization raises sev-
eral ethical issues, such as preventing exploitation, ensur-
ing fairness to study participants, and balancing costs and 
benefits  (59).  Some  articles  showed  that  commercializa-
tion, in general, tended to decrease public trust in biobanks 
(26,34,69), although it did not completely diminish it.
A typical example of commercialization in biobanking is 
pharmacogenomics research supported by pharmaceu-
tical  companies  (26,109,110).  They  support  research 
that could eventually improve treatment, but they 
also hope that the results of such research could prove 
very profitable in the future. Also, gene patents are po-
tentially very profitable, so many companies are willing to 
support such investigation to achieve future profits (9,111). 
But, is it ethical to create such financial benefits from free 
donations and who has the right to a share in these prof-
its? How should costs and benefits be balanced and how 
should intellectual property be shared between compa-
nies, researchers, and participants?
These dilemmas have not been resolved in the literature. 
In fact, given how quickly some major players in the pri-
vate sector are moving toward commercialization, there is 
insufficient discussion in the present literature about these 
very real and pressing (and not merely hypothetical) issues. 
We believe that people generally understand that the part-
nership of research and commercial interest could also be 
very productive and should not be seen as a threat to their 
interests. Ongoing discussion on these issues, based on 
some concrete examples from real life – both positive and 
negative – is certainly needed.
Role of ethics Review Boards
The role of ERBs will not necessarily be the same in all in-
stitutions (6,112,113). ERBs work under ethical and legal 
frameworks and national legislation, which provide pro-
tection of participants and ensure appropriate use of their 
samples (114-117). As mentioned previously, the role of 
ERBs is crucial for ensuring public trust. ERBs are safeguards 
of participants’ interest and thus have a very important role 
in the process. Also, the whole development of biobanks 
and their integration depends on ERBs. Despite that, one 
study showed that members of ethical boards are not nec-
essarily comfortable or satisfied with their present role in 
biobanks. They want to be more engaged in the whole 
process of biobanking (118). But, this decision lies with in-
stitutions. As ERBs play such a critical role, we believe that 
there should be more literature that could provide guid-
ance and help improve the quality of their contribution in 
the process of reviewing biobanking activities.
Data exchange
Many authors agree that international collaboration is ex-
tremely useful and that it should be encouraged, as long 
as it exposes donors to minimal risk. Data exchange be-
tween research groups who work on different biobanks can 
facilitate research, but it also requires a removal of a major 
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Thus, many authors see a need for greater international har-
monization of the principles of biobanking and its design, 
and a major role for ERBs in the regulation of that process 
(6,7,26,119,120). Several institutions have already established 
national  and  international  cooperation  rules  and  norms 
(5,26,121-127). Some of these rules are even published in 
detail (20,21). The main ethical issue of integration and har-
monization of the data sets that biobanks contain is the pro-
tection of participants’ privacy. This is why ERBs must have 
an important role in overseeing this harmonization (6).
There is also a matter of digital data in biobanks, espe-
cially sharing and storing the data in public repositories. 
Many journals have over the past few years established the 
need for making the research data publicly available, rais-
ing mixed feelings on the issues related to confidentiali-
ty (128). An overview of the journal policies indicates that 
some journals (such as notably Genetics) actually require all 
the materials to be made publicly available before publi-
cation of the research results. This requirement can make 
strong impact on the research output, since disclosure of 
this type of information for some types of biobanks (ie, iso-
lated populations) can present a potential and true risk for 
confidentiality breach. If we assume that publication of re-
search results requires public disclosure of all material, in-
cluding genetics and even pedigree information, one can 
envision that the use of a relatively small number of ge-
netic  markers  and  cross-comparison  with  the  pedigree 
can lead to serious confidentiality breach and possibility to 
misuse such information. The very existence of such mech-
anisms is questionable; since another study showed that 
even when less strict mechanisms were in place, research-
ers are reluctant to share the raw data in order to protect 
participants’ confidentiality (129).
Benefit sharing
Benefit sharing is a very sensitive issue and it is rarely dis-
cussed. Benefit from the research results, especially the fi-
nancial benefit, could be shared among participants, com-
munities that take part in research, researchers, and their 
institutions. There is a substantial interest from the industry in 
this research, so that generation of intellectual property and 
benefits over time is not unlikely. In terms of benefit sharing, 
biobanks must strike a balance between many competing 
interest from various stakeholders in the process (9).
There is a high level of agreement between the authors 
that donors of biological materials should not be paid. Do-
nors will eventually profit from the results that will improve 
future diagnosis and treatment of the diseases in the pop-
ulation (130). It is suggested that all negative reactions that 
may raise among the donors could be prevented by pro-
fessional and responsible information sharing, education 
of the donors about the research process, and complete 
transparency over the outcomes of the research in terms 
of both new knowledge that was generated and the in-
come and its distribution (59).
Ownership of the biological samples and data
Another infrequently discussed topic in the literature is 
ownership of samples. It presents ethical and legal issue in 
biobanking. What happens when a participant donates a 
part of body to a biobank? Could biobanks become own-
ers of the sample or does it remain in the ownership of the 
participants? One author has recently explored this issue 
in great depth and concluded that the legal position on 
ownership remained unsettled (26). Other authors take the 
position that complete anonymization would practically 
make biological materials ownerless, but that in all other 
instances the donors maintain ownership and should be 
able to withdraw both their consent and their biological 
material donated to the biobank (131,132).
Most biobanks have agreed to be custodians or trustees, in-
stead of owners, of samples (130,133-135). One author sug-
gested that samples should be the shared property of do-
nors, researchers, and institutions (64). But, this issue clearly 
remains insufficiently discussed and it is unresolved.
A comparison of positions of different stakeholders (eg, 
ethical boards, research participants, researchers, and 
institutions)
In the biobank development process, it is extremely im-
portant to consider the different opinions of all stakehold-
ers involved in the research process. Many articles have in-
vestigated opinions of the ERB, researchers, medical staff, 
and potential participants in order to help build ethical 
and legal frameworks for biobanks.
The greatest number of studies was conducted to investi-
gate participants’ attitudes. Generally, participants have pos-
itive attitudes toward biobanks and many people are inter-
ested in participating (15,19,69,76-79,136,137). They believe 
strongly in the better future that biobank-related biomedi-
cal research could offer to them and their offspring. In ad-
dition, several studies investigated opinions of pregnant 
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diatric biobanks. Most of them shared positive attitudes to-
ward pediatric biobanks (80-82). In spite of that, participants’ 
concerns were always present, such as adequate protection 
of privacy (69). One of the frequently reported problems 
was that they did not understand the aims of research fully 
(83-86), but nonetheless they still agreed to participate. One 
study discovered that the domains of the information sheet/
consent form that were best understood were the nature 
and benefits from the study and voluntary nature of par-
ticipation (138). Less understanding was reported for risks 
of involvement, confidentiality, and experimental nature of 
research. Expectations of participants were generally simi-
lar to this. Most of them wanted control over their access to 
information, return of the results to them, and involvement 
of ERBs (15,71,72,93). One study (139) focused on investigat-
ing the opinion of the selected sub-sample of the people 
who refused to donate their samples for genetic research. 
The main concern was their general mistrust over sharing of 
their DNA information.
Comparisons  of  attitudes  toward  biobanks  between  the 
general public and technical experts showed that they were 
quite different. For example, one article clearly showed that 
ERB members, researchers, and participants had a rather dif-
ferent opinion about which information should be includ-
ed in the consent form (140). Generally, experts were more 
positive about biobanking because they had greater knowl-
edge of the issue than non-experts and they all shared very 
positive attitudes (87,141). However, even the experts did 
not  always  share  their  enthusiasm  toward  all  aspects  of 
biobanking (134). Similar findings were noted by ERB mem-
bers: although they would often disagree on many issues 
relevant  to  biobanking,  a  broad  general  agreement  was 
nearly always present among them (112,118,142).
Only one article interviewed leaders of ethno-cultural com-
munities, who are a relatively frequent category of sponsors 
and beneficiaries of biobanks (143). The authors concluded 
that involving leaders in development of biobanks can be 
very useful. Also, educating them about aims and scope of 
biobanking is essential for the success and sustainability of 
research projects. The authors concluded that an improved 
approach to education of community leaders would sub-
stantially improve the whole process of biobanking.
legislative framework for biobanks and other emerging 
issues
In the most developed countries, governments are be-
ginning to pass the formal legislation that governs 
the principles of development and utilization of biobanks 
with human samples. One of the most advanced in this re-
gard is Iceland, where the DeCode Genomics Company has 
been utilizing the genetic heritage, phenotypes, and deep 
genealogies of most living Icelanders. The Icelandic govern-
ment has passed “The Biobank Act” to regulate this unusual 
public-private partnership (144). This gave the researchers 
from Iceland substantial returns in terms of research com-
petitiveness, but the financial benefits have not been re-
ciprocal for their industry partner. Other countries where 
a substantive legislative framework is being developed in-
clude France, Estonia, Spain, Scandinavian countries, the 
United States, and the United Kingdom (145-150).
One of the interesting strategic debates relevant to the de-
velopment of national biobanks was whether it was better 
to invest in the existing large collections of biologic mate-
rials from longitudinal epidemiological cohorts and enrich 
it with additional measurements to harmonize several ex-
isting data sets or to build them brand new and from the 
start. While the debate over this issue in the USA has pos-
sibly delayed research progress and handed the competi-
tive edge to the Europeans, even if only temporarily, the 
Dutch government supported the existing biobanks (151), 
while the UK government invested in the entirely new “UK 
Biobank”  with  at  least  500 000  participants  (152,153).  In 
France, an interesting idea was proposed that a massive 
biobank could be developed very quickly and cost-effec-
tively by recruiting people who volunteer to give blood in 
transfusion centers, as they would also be likely to take part 
in biobanking research (154). Other ideas included setting 
up biobanks as charitable trusts (155).
DIsCussION
In this systematic review, we assessed the quantity of re-
search on ethical aspects of biobanking and systematically 
addressed the most important ethical dilemmas. We at-
tempted to remain impartial on all ethical issues and pres-
ent how different issues are understood and viewed by dif-
ferent authors. We described how ethical guidelines were 
viewed among different authors and institutions, but the 
main ethical principles of respect, benefice, justice, and 
minimizing harm remained a constant motive. Generally, 
we observed that there was a consensus on these well-
recognized ethical issues, but rapid biobank development 
continues to provide new issues that are often difficult to 
follow and discuss. Many issues have created dilemmas 
that are yet to be resolved, and the consensus still needs 
to be reached.273 Budimir et al: Ethical aspects of biobanks
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Different ethical issues can sometimes arise from different 
types of biobanks – or sometimes the same issues, but to 
different extent. It is clear, for example, that the return of an 
epidemiological result to the participant will not provoke 
the same level of debate as the return of his/her genetic in-
formation. Similarly, collecting cancer samples is not asso-
ciated with the same level of concern as, for example, col-
lecting of the samples to be used in creation of pluripotent 
cells that will be transplanted into humans. The biobanks 
that deal with the latter nature of work are probably the 
most controversial issue in this domain. In addition to this, 
prior to the development of genetic biobanks, ethical is-
sues in biobanking were rarely discussed in the scientific 
literature. Collections of human tissues have a very long 
history, but they did not raise nearly as many ethical con-
cerns throughout decades of research as biobanks did in 
the past few years. Post-genomic era exposed and aug-
mented many existing ethical problems and also brought 
to surface some new ones. With enormous advances in 
genetic research, ethical issues are changing over time to-
gether with development of science and technology. We 
believe that this trend will continue in the future, but the 
directions that this research will eventually assume, and 
the ethical issues that may still arise, are very difficult to an-
ticipate. Therefore, there is a need for enactment of legisla-
tion regarding the collection and use of human biological 
materials and associated data.
Ethical issues in biobanks have emerged as important is-
sues  in  publishing  research  from  such  sources.  Interna-
tional Committee of Medical Journal Editors (http://www.
icmje.org) does not address ethical issues related to pub-
lishing results from biobanks. There is no guideline for re-
porting results from biobank research, as judged by the 
information on Enhancing the Quality and Transparency 
of Health Research (EQUATOR) network. These organiza-
tions could use this systematic review to address the most 
important issues related to biobanks and data publishing. 
However, there is some relevant information at Minimum 
Information for Biological and Biomedical Investigations 
(http://www.mibbi.org/index.php/MIBBI_portal).  There 
is another similar guideline concerning the quality of re-
porting in genetic association studies results. A group of 
experts proposed guiding principles for reporting genetic 
results as an extension of the previous STROBE Statement 
and called it the STrengthening the REporting of Genetic 
Association Studies (STREGA) Statement (156). The STRE-
GA recommendations are available at http://www.strega-
statement.org/ and all journals are endorsed to use them. 
Some  official  guidelines  or  recommendations  concern-
ing research on human participants are developed, such 
as Convention on Human Right and Biomedicine, created 
by the Council of Europe in 1997 (http://conventions.coe.
int/Treaty/Commun/QueVoulezVous.asp?NT=164&CM=
8&DF=23/04/2011&CL=ENG)  and  the  International  Ethi-
cal Guidelines for Biomedical Research Involving Human 
Subjects, created by the Council for International Organi-
zations  of  Medical  Sciences  in  2002  (http://www.cioms.
ch/publications/guidelines/guidelines_nov_2002_blurb.
htm). Both relate to the main ethical principles on humans 
in medical research. In addition to this, the OECD Council 
in 2009 adopted a Recommendation on Human Biobanks 
and Genetic Research Databases (HBGRD), the guidelines 
for the management, governance, access, and use of HB-
GRDs in a manner respectful of participants (http://www.
oecd.org/sti/ biotechnology/hbgrd). Since additional offi-
cial guidelines or recommendations specifically address-
ing biobanks should be developed, one of the conclusions 
of this study is to raise researchers’ awareness and consider 
creation of the biobank-related publishing guidelines.
Implications of the ethics discussion of biobanks are in-
teresting not just for the sake of biobanks themselves, but 
also for the very foundation of the future medicine. The 
future will inevitably bring personalized medicine, which 
will share a number of similarities with the contemporary 
biobanks – need to protect sensitive information, levels of 
accessibility, the need to prevent data misuse, and the pos-
sibility to predict individual health-related outcomes based 
on the genomic information.
After a systematic analysis of all articles published in the 
last two decades that were concerned with ethical impli-
cations of biobanking, we conclude that the focus on ethi-
cal aspects was strongly prominent throughout the whole 
biobanking research field development, albeit published 
by research groups in a very limited set of (highly devel-
oped) countries and their leading academic institutions. 
Ethical  issues  in  conjunction  with  legal  frameworks  are 
major steps in biobanking development, but many unre-
solved problems remain. With further development of this 
field  and  the  increasingly  complex  structure  of  human 
biobanks, these issues will likely continue to arise and ac-
cumulate, hence requiring constant re-appraisal and dis-
cussion on ethical issues.
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